<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00092495</url>
  </required_header>
  <id_info>
    <org_study_id>V501-016</org_study_id>
    <secondary_id>2004_083</secondary_id>
    <nct_id>NCT00092495</nct_id>
  </id_info>
  <brief_title>Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)</brief_title>
  <official_title>A Study to Demonstrate Immunogenicity and Tolerability of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents, and To Determine End-Expiry Specifications for the Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to determine if an investigational vaccine Gardasil
      (V501) with 4 components will provide an immune response and will be well tolerated in
      pre-adolescents and adolescents.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Who Seroconverted for HPV 6 by Week 4 Postdose 3</measure>
    <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
    <description>Seroconversion is defined as going from seronegative to seropositive.
Seropositivity is defined as an anti-HPV 6 titer ≥ 20 milliMerck units per milliliter (mMU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) for HPV 6 by Week 4 Postdose 3</measure>
    <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Seroconverted for HPV 11 by Week 4 Postdose 3</measure>
    <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
    <description>Seroconversion is defined as going from seronegative to seropositive.
Seropositivity is defined as an anti-HPV 11 titer ≥ 16 milliMerck units per milliliter (mMU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) for HPV 11 by Week 4 Postdose 3</measure>
    <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Seroconverted for HPV 16 by Week 4 Postdose 3</measure>
    <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
    <description>Seropositivity is defined as an anti-HPV 16 titer ≥ 20 milliMerck units per milliliter (mMU/mL). Seroconversion is defined as going from seronegative to seropositive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) for HPV 16 by Week 4 Postdose 3</measure>
    <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Seroconverted for HPV 16 by Week 4 Postdose 3</measure>
    <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
    <description>Seroconversion is defined as going from seronegative to seropositive.
Seropositivity is defined as an anti-HPV 16 titer ≥ 20 milliMerck units per milliliter (mMU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Seroconverted for HPV 18 by Week 4 Postdose 3</measure>
    <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
    <description>Seroconversion is defined as going from seronegative to seropositive.
Seropositivity is defined as an anti-HPV 18 titer ≥ 24 milliMerck units per milliliter (mMU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) for HPV 18 by Week 4 Postdose 3</measure>
    <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3055</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Genital Warts</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100% Formulation qHPV Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60% Formulation qHPV Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40% Formulation qHPV Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20% Formulation qHPV Vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine</intervention_name>
    <description>qHPV Vaccine (20, 40, 60 or 100% dose formulation) 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>V501</other_name>
    <other_name>Gardasil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adolescents and pre-adolescents with no prior sexual history

          -  Healthy women who have an intact uterus with lifetime history of 0-4 sexual partners

        Exclusion Criteria:

          -  Prior Human Papillomavirus (HPV) vaccination

          -  Prior abnormal Paps

          -  Prior history of genital warts
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>23 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsagué X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF Jr, Reisinger KS; Protocol 016 Study Group. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006 Nov;118(5):2135-45.</citation>
    <PMID>17079588</PMID>
  </reference>
  <reference>
    <citation>Barr E, Gause CK, Bautista OM, Railkar RA, Lupinacci LC, Insinga RP, Sings HL, Haupt RM. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women. Am J Obstet Gynecol. 2008 Mar;198(3):261.e1-11. doi: 10.1016/j.ajog.2007.09.001.</citation>
    <PMID>18313445</PMID>
  </reference>
  <reference>
    <citation>Perez G, Lazcano-Ponce E, Hernandez-Avila M, García PJ, Muñoz N, Villa LL, Bryan J, Taddeo FJ, Lu S, Esser MT, Vuocolo S, Sattler C, Barr E. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer. 2008 Mar 15;122(6):1311-8.</citation>
    <PMID>18000825</PMID>
  </reference>
  <reference>
    <citation>Giuliano AR, Lazcano-Ponce E, Villa L, Nolan T, Marchant C, Radley D, Golm G, McCarroll K, Yu J, Esser MT, Vuocolo SC, Barr E. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis. 2007 Oct 15;196(8):1153-62. Epub 2007 Sep 17.</citation>
    <PMID>17955433</PMID>
  </reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2004</study_first_submitted>
  <study_first_submitted_qc>September 24, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2004</study_first_posted>
  <results_first_submitted>February 15, 2010</results_first_submitted>
  <results_first_submitted_qc>February 15, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 8, 2010</results_first_posted>
  <last_update_submitted>December 29, 2014</last_update_submitted>
  <last_update_submitted_qc>December 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>20% Formulation qHPV Vaccine</title>
          <description>Subjects in this group received a 20% dose formulation of the quadrivalent human papillomavirus (qHPV) vaccine at Day 1, Month 2, and Month 6.</description>
        </group>
        <group group_id="P2">
          <title>40% Formulation qHPV Vaccine</title>
          <description>Subjects in this group received a 40% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6.</description>
        </group>
        <group group_id="P3">
          <title>60% Formulation qHPV Vaccine</title>
          <description>Subjects in this group received a 60% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6</description>
        </group>
        <group group_id="P4">
          <title>100% Formulation qHPV Vaccine</title>
          <description>Subjects in this group received a 100% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6.</description>
        </group>
        <group group_id="P5">
          <title>Extension Study</title>
          <description>Extension Study: This group includes 12 subjects who participated in the base study and received either a partial dose formulation of the quadrivalent HPV vaccine in the base study and did not meet the protocol specified criteria for seroconversion, or subjects who, due to pregnancy, received 1 or 2 doses of the quadrivalent HPV vaccine in the base study and remained in the study through Month 7. The Extension Period began after all patients had completed the Month 7 follow-up period. Subjects designated as &quot;Completed Period&quot; are those who at the end of the study had received three injections of quadrivalent HPV vaccine and completed all follow-up visits. Subjects designated as &quot;Not Completed&quot; are those who: a) Received all three vaccinations, but did not complete follow-up; b) Did not receive all vaccinations, but completed follow-up, or c) Did not receive all vaccinations, and did not complete follow-up.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Base Study Vaccination Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="504"/>
                <participants group_id="P2" count="514"/>
                <participants group_id="P3" count="508"/>
                <participants group_id="P4" count="1529"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>With Long-term Follow-up *</title>
              <participants_list>
                <participants group_id="P1" count="2">Subjects received fewer than 3 doses of vaccinations and entered the long-term follow-up period</participants>
                <participants group_id="P2" count="2">Subjects received fewer than 3 doses of vaccinations and entered the long-term follow-up period</participants>
                <participants group_id="P3" count="6">Subjects received fewer than 3 doses of vaccinations and entered the long-term follow-up period</participants>
                <participants group_id="P4" count="10">Subjects received fewer than 3 doses of vaccinations and entered the long-term follow-up period</participants>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Without Long-term Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="34">Subjects discontinued on or before Month 7 and did not enter the long-term follow-up period</participants>
                <participants group_id="P2" count="20">Subjects discontinued on or before Month 7 and did not enter the long-term follow-up period</participants>
                <participants group_id="P3" count="28">Subjects discontinued on or before Month 7 and did not enter the long-term follow-up period</participants>
                <participants group_id="P4" count="73">Subjects discontinued on or before Month 7 and did not enter the long-term follow-up period</participants>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="467">Completed 3 vaccinations; entered the long-term follow-up or completed the study per-protocol</participants>
                <participants group_id="P2" count="492">Completed 3 vaccinations; entered the long-term follow-up or completed the study per-protocol</participants>
                <participants group_id="P3" count="474">Completed 3 vaccinations; entered the long-term follow-up or completed the study per-protocol</participants>
                <participants group_id="P4" count="1441">Completed 3 vaccinations; entered the long-term follow-up or completed the study per-protocol</participants>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="88"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized Not Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Extended</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>*Clinical AE</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>*Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>*Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="36"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parent Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Base Study Follow-up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="115">Protocol amended to extend follow-up for 10-15 year old subjects to Month 12 (6 months Postdose 3)</participants>
                <participants group_id="P2" count="125">Protocol amended to extend follow-up for 10-15 year old subjects to Month 12 (6 months Postdose 3)</participants>
                <participants group_id="P3" count="130">Protocol amended to extend follow-up for 10-15 year old subjects to Month 12 (6 months Postdose 3)</participants>
                <participants group_id="P4" count="460">Protocol amended to extend follow-up for 10-15 year old subjects to Month 12 (6 months Postdose 3)</participants>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="122"/>
                <participants group_id="P3" count="126"/>
                <participants group_id="P4" count="446"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Extended</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>20% Formulation qHPV Vaccine</title>
          <description>Subjects in this group received a 20% dose formulation of the quadrivalent human papillomavirus (qHPV) vaccine at Day 1, Month 2, and Month 6.</description>
        </group>
        <group group_id="B2">
          <title>40% Formulation qHPV Vaccine</title>
          <description>Subjects in this group received a 40% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6.</description>
        </group>
        <group group_id="B3">
          <title>60% Formulation qHPV Vaccine</title>
          <description>Subjects in this group received a 60% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6</description>
        </group>
        <group group_id="B4">
          <title>100% Formulation qHPV Vaccine</title>
          <description>Subjects in this group received a 100% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="504"/>
            <count group_id="B2" value="514"/>
            <count group_id="B3" value="508"/>
            <count group_id="B4" value="1529"/>
            <count group_id="B5" value="3055"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.2" lower_limit="10" upper_limit="23"/>
                    <measurement group_id="B2" value="16.5" lower_limit="10" upper_limit="24"/>
                    <measurement group_id="B3" value="16.2" lower_limit="10" upper_limit="23"/>
                    <measurement group_id="B4" value="15.1" lower_limit="10" upper_limit="23"/>
                    <measurement group_id="B5" value="15.7" spread="10" lower_limit="10" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>10 to 11 Years of Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="302"/>
                    <measurement group_id="B5" value="528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 to 13 Years of Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="101"/>
                    <measurement group_id="B4" value="370"/>
                    <measurement group_id="B5" value="676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14 to 15 Years of Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="344"/>
                    <measurement group_id="B5" value="571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 to 17 Years of Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="77"/>
                    <measurement group_id="B5" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 to 19 Years of Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="125"/>
                    <measurement group_id="B5" value="316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 to 21 Years of Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="165"/>
                    <measurement group_id="B5" value="434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>22 to 23 Years of Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="146"/>
                    <measurement group_id="B5" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Over 23 Years of Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="504"/>
                    <measurement group_id="B2" value="514"/>
                    <measurement group_id="B3" value="508"/>
                    <measurement group_id="B4" value="1019"/>
                    <measurement group_id="B5" value="2545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="510"/>
                    <measurement group_id="B5" value="510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Seroconverted for HPV 6 by Week 4 Postdose 3</title>
        <description>Seroconversion is defined as going from seronegative to seropositive.
Seropositivity is defined as an anti-HPV 6 titer ≥ 20 milliMerck units per milliliter (mMU/mL).</description>
        <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to subjects receiving 100% dosage.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 10-15 Years</title>
          </group>
          <group group_id="O2">
            <title>Boys 10-15 Years</title>
          </group>
          <group group_id="O3">
            <title>Women 16-23 Years</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Seroconverted for HPV 6 by Week 4 Postdose 3</title>
          <description>Seroconversion is defined as going from seronegative to seropositive.
Seropositivity is defined as an anti-HPV 6 titer ≥ 20 milliMerck units per milliliter (mMU/mL).</description>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to subjects receiving 100% dosage.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="428"/>
                <count group_id="O3" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV 6 ≥ 20 mMU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="423"/>
                    <measurement group_id="O2" value="428"/>
                    <measurement group_id="O3" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 6 &lt; 20 mMU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (girls - women) must be greater than -5%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions
Miettinen and Nurminen, Stat Med 1985;4:213-26</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (boys - women) must be greater than -5%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions
Miettinen and Nurminen, Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) for HPV 6 by Week 4 Postdose 3</title>
        <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
        <population>: Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to subjects receiving 100% dosage.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 10-15 Years</title>
          </group>
          <group group_id="O2">
            <title>Boys 10-15 Years</title>
          </group>
          <group group_id="O3">
            <title>Women 16-23 Years</title>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) for HPV 6 by Week 4 Postdose 3</title>
          <population>: Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to subjects receiving 100% dosage.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="428"/>
                <count group_id="O3" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="987.3" lower_limit="905.0" upper_limit="1077.0"/>
                    <measurement group_id="O2" value="1116.1" lower_limit="1022.7" upper_limit="1218.1"/>
                    <measurement group_id="O3" value="603.0" lower_limit="548.5" upper_limit="662.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (girls/women) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region and comparison group.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (boys/women) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region and comparison group.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Seroconverted for HPV 6 by Week 4 Postdose 3</title>
        <description>Seroconversion is defined as going from seronegative to seropositive.
Seropositivity is defined as an anti-HPV 6 titer ≥ 20 milliMerck units per milliliter (mMU/mL).</description>
        <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to female subjects 10-15 years and 16-23 years.</population>
        <group_list>
          <group group_id="O1">
            <title>20% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 20% dose formulation of the quadrivalent human papillomavirus (qHPV) vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
          <group group_id="O2">
            <title>40% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 40% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
          <group group_id="O3">
            <title>60% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 60% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O4">
            <title>100% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 100% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Seroconverted for HPV 6 by Week 4 Postdose 3</title>
          <description>Seroconversion is defined as going from seronegative to seropositive.
Seropositivity is defined as an anti-HPV 6 titer ≥ 20 milliMerck units per milliliter (mMU/mL).</description>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to female subjects 10-15 years and 16-23 years.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="391"/>
                <count group_id="O3" value="364"/>
                <count group_id="O4" value="743"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV 6 ≥ 20 mMU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="372"/>
                    <measurement group_id="O2" value="391"/>
                    <measurement group_id="O3" value="363"/>
                    <measurement group_id="O4" value="743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 6 &lt; 20 mMU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (partial dose - full dose) must be greater than -5%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions
Miettinen and Nurminen, Stat Med 1985;4:213-26</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (partial dose - full dose) must be greater than -5%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions
Miettinen and Nurminen, Stat Med 1985;4:213-26</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (partial dose - full dose) must be greater than -5%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions
Miettinen and Nurminen, Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) for HPV 6 by Week 4 Postdose 3</title>
        <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to female subjects 10-15 years and 16-23 years.</population>
        <group_list>
          <group group_id="O1">
            <title>20% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 20% dose formulation of the quadrivalent human papillomavirus (qHPV) vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
          <group group_id="O2">
            <title>40% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 40% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
          <group group_id="O3">
            <title>60% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 60% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O4">
            <title>100% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 100% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) for HPV 6 by Week 4 Postdose 3</title>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to female subjects 10-15 years and 16-23 years.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="391"/>
                <count group_id="O3" value="364"/>
                <count group_id="O4" value="743"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="584.2" lower_limit="526.7" upper_limit="647.9"/>
                    <measurement group_id="O2" value="704.5" lower_limit="636.6" upper_limit="779.7"/>
                    <measurement group_id="O3" value="707.5" lower_limit="632.5" upper_limit="791.2"/>
                    <measurement group_id="O4" value="798.4" lower_limit="747.1" upper_limit="853.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (partial dose/full dose) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region and comparison group.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (partial dose/full dose) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region and comparison group.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (partial dose/full dose) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region and comparison group.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Seroconverted for HPV 11 by Week 4 Postdose 3</title>
        <description>Seroconversion is defined as going from seronegative to seropositive.
Seropositivity is defined as an anti-HPV 11 titer ≥ 16 milliMerck units per milliliter (mMU/mL).</description>
        <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to subjects receiving 100% dosage.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 10-15 Years</title>
          </group>
          <group group_id="O2">
            <title>Boys 10-15 Years</title>
          </group>
          <group group_id="O3">
            <title>Women 16-23 Years</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Seroconverted for HPV 11 by Week 4 Postdose 3</title>
          <description>Seroconversion is defined as going from seronegative to seropositive.
Seropositivity is defined as an anti-HPV 11 titer ≥ 16 milliMerck units per milliliter (mMU/mL).</description>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to subjects receiving 100% dosage.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="428"/>
                <count group_id="O3" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV 11 ≥ 16 mMU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="423"/>
                    <measurement group_id="O2" value="428"/>
                    <measurement group_id="O3" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 11 &lt; 16 mMU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (girls - women) must be greater than -5%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions
Miettinen and Nurminen, Stat Med 1985;4:213-26</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (boys - women) must be greater than -5%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions
Miettinen and Nurminen, Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) for HPV 11 by Week 4 Postdose 3</title>
        <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to subjects receiving 100% dosage.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 10-15 Years</title>
          </group>
          <group group_id="O2">
            <title>Boys 10-15 Years</title>
          </group>
          <group group_id="O3">
            <title>Women 16-23 Years</title>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) for HPV 11 by Week 4 Postdose 3</title>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to subjects receiving 100% dosage.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="428"/>
                <count group_id="O3" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1264.0" lower_limit="1153.2" upper_limit="1385.4"/>
                    <measurement group_id="O2" value="1396.5" lower_limit="1271.4" upper_limit="1534.0"/>
                    <measurement group_id="O3" value="739.2" lower_limit="665.6" upper_limit="821.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (girls/women) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region and comparison group</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (boys/women) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region and comparison group</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Seroconverted for HPV 11 by Week 4 Postdose 3</title>
        <description>Seroconversion is defined as going from seronegative to seropositive.
Seropositivity is defined as an anti-HPV 11 titer ≥ 16 milliMerck units per milliliter (mMU/mL).</description>
        <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to female subjects 10-15 years and 16-23 years.</population>
        <group_list>
          <group group_id="O1">
            <title>20% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 20% dose formulation of the quadrivalent human papillomavirus (qHPV) vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
          <group group_id="O2">
            <title>40% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 40% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
          <group group_id="O3">
            <title>60% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 60% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O4">
            <title>100% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 100% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Seroconverted for HPV 11 by Week 4 Postdose 3</title>
          <description>Seroconversion is defined as going from seronegative to seropositive.
Seropositivity is defined as an anti-HPV 11 titer ≥ 16 milliMerck units per milliliter (mMU/mL).</description>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to female subjects 10-15 years and 16-23 years.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
                <count group_id="O2" value="391"/>
                <count group_id="O3" value="365"/>
                <count group_id="O4" value="743"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV 11 ≥ 16 mMU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="373"/>
                    <measurement group_id="O2" value="391"/>
                    <measurement group_id="O3" value="364"/>
                    <measurement group_id="O4" value="743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 11 &lt; 16 mMU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (partial dose - full dose) must be greater than -5%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions
Miettinen and Nurminen, Stat Med 1985;4:213-26</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (partial dose - full dose) must be greater than -5%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions
Miettinen and Nurminen, Stat Med 1985;4:213-26</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (partial dose - full dose) must be greater than -5%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions
Miettinen and Nurminen, Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) for HPV 11 by Week 4 Postdose 3</title>
        <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
        <population>: Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to female subjects 10-15 years and 16-23 years.</population>
        <group_list>
          <group group_id="O1">
            <title>20% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 20% dose formulation of the quadrivalent human papillomavirus (qHPV) vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
          <group group_id="O2">
            <title>40% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 40% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
          <group group_id="O3">
            <title>60% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 60% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O4">
            <title>100% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 100% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) for HPV 11 by Week 4 Postdose 3</title>
          <population>: Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to female subjects 10-15 years and 16-23 years.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
                <count group_id="O2" value="391"/>
                <count group_id="O3" value="365"/>
                <count group_id="O4" value="743"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="632.1" lower_limit="565.2" upper_limit="706.8"/>
                    <measurement group_id="O2" value="804.7" lower_limit="723.9" upper_limit="894.4"/>
                    <measurement group_id="O3" value="836.2" lower_limit="743.7" upper_limit="940.2"/>
                    <measurement group_id="O4" value="1003.2" lower_limit="934.0" upper_limit="1077.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (partial dose/full dose) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region and comparison group.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (partial dose/full dose) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region and comparison group</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (partial dose/full dose) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region and comparison group.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Seroconverted for HPV 16 by Week 4 Postdose 3</title>
        <description>Seropositivity is defined as an anti-HPV 16 titer ≥ 20 milliMerck units per milliliter (mMU/mL). Seroconversion is defined as going from seronegative to seropositive.</description>
        <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to subjects receiving 100% dosage.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 10-15 Years</title>
          </group>
          <group group_id="O2">
            <title>Boys 10-15 Years</title>
          </group>
          <group group_id="O3">
            <title>Women 16-23 Years</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Seroconverted for HPV 16 by Week 4 Postdose 3</title>
          <description>Seropositivity is defined as an anti-HPV 16 titer ≥ 20 milliMerck units per milliliter (mMU/mL). Seroconversion is defined as going from seronegative to seropositive.</description>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to subjects receiving 100% dosage.</population>
          <units>mMU/mL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="427"/>
                <count group_id="O3" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV 16 ≥ 20 mMU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="424"/>
                    <measurement group_id="O2" value="427"/>
                    <measurement group_id="O3" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 16 &lt; 20 mMU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (girls - women) must be greater than -5%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions
Miettinen and Nurminen, Stat Med 1985;4:213-26</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (boys - women) must be greater than -5%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions
Miettinen and Nurminen, Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) for HPV 16 by Week 4 Postdose 3</title>
        <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to subjects receiving 100% dosage.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 10-15 Years</title>
          </group>
          <group group_id="O2">
            <title>Boys 10-15 Years</title>
          </group>
          <group group_id="O3">
            <title>Women 16-23 Years</title>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) for HPV 16 by Week 4 Postdose 3</title>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to subjects receiving 100% dosage.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="427"/>
                <count group_id="O3" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4848.8" lower_limit="4350.2" upper_limit="5404.5"/>
                    <measurement group_id="O2" value="5923.0" lower_limit="5325.2" upper_limit="6587.9"/>
                    <measurement group_id="O3" value="2753.0" lower_limit="2400.5" upper_limit="3157.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (girls/women) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region and comparison group.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (boys/women) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region and comparison group.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Seroconverted for HPV 16 by Week 4 Postdose 3</title>
        <description>Seroconversion is defined as going from seronegative to seropositive.
Seropositivity is defined as an anti-HPV 16 titer ≥ 20 milliMerck units per milliliter (mMU/mL).</description>
        <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to female subjects 10-15 years and 16-23 years.</population>
        <group_list>
          <group group_id="O1">
            <title>20% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 20% dose formulation of the quadrivalent human papillomavirus (qHPV) vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
          <group group_id="O2">
            <title>40% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 40% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
          <group group_id="O3">
            <title>60% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 60% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O4">
            <title>100% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 100% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Seroconverted for HPV 16 by Week 4 Postdose 3</title>
          <description>Seroconversion is defined as going from seronegative to seropositive.
Seropositivity is defined as an anti-HPV 16 titer ≥ 20 milliMerck units per milliliter (mMU/mL).</description>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to female subjects 10-15 years and 16-23 years.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="365"/>
                <count group_id="O2" value="375"/>
                <count group_id="O3" value="365"/>
                <count group_id="O4" value="730"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV 16 ≥ 20 mMU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="365"/>
                    <measurement group_id="O2" value="375"/>
                    <measurement group_id="O3" value="364"/>
                    <measurement group_id="O4" value="730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 16 &lt; 20 mMU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (partial dose - full dose) must be greater than -5%.</non_inferiority_desc>
            <p_value>&lt;0.01</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions
Miettinen and Nurminen, Stat Med 1985;4:213-26</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (partial dose - full dose) must be greater than -5%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions
Miettinen and Nurminen, Stat Med 1985;4:213-26</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (partial dose - full dose) must be greater than -5%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions
Miettinen and Nurminen, Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) for HPV 16 by Week 4 Postdose 3</title>
        <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to female subjects 10-15 years and 16-23 years.</population>
        <group_list>
          <group group_id="O1">
            <title>20% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 20% dose formulation of the quadrivalent human papillomavirus (qHPV) vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
          <group group_id="O2">
            <title>40% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 40% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
          <group group_id="O3">
            <title>60% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 60% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O4">
            <title>100% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 100% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) for HPV 16 by Week 4 Postdose 3</title>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to female subjects 10-15 years and 16-23 years.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="365"/>
                <count group_id="O2" value="375"/>
                <count group_id="O3" value="365"/>
                <count group_id="O4" value="730"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2401.1" lower_limit="2084.0" upper_limit="2766.6"/>
                    <measurement group_id="O2" value="2963.3" lower_limit="2593.3" upper_limit="3386.0"/>
                    <measurement group_id="O3" value="3105.3" lower_limit="2692.8" upper_limit="3581.1"/>
                    <measurement group_id="O4" value="3824.6" lower_limit="3504.4" upper_limit="4174.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (partial dose/full dose) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region and comparison group.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (partial dose/full dose) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region and comparison group.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (partial dose/full dose) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region and comparison group.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Seroconverted for HPV 18 by Week 4 Postdose 3</title>
        <description>Seroconversion is defined as going from seronegative to seropositive.
Seropositivity is defined as an anti-HPV 18 titer ≥ 24 milliMerck units per milliliter (mMU/mL).</description>
        <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to subjects receiving 100% dosage.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 10-15 Years</title>
          </group>
          <group group_id="O2">
            <title>Boys 10-15 Years</title>
          </group>
          <group group_id="O3">
            <title>Women 16-23 Years</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Seroconverted for HPV 18 by Week 4 Postdose 3</title>
          <description>Seroconversion is defined as going from seronegative to seropositive.
Seropositivity is defined as an anti-HPV 18 titer ≥ 24 milliMerck units per milliliter (mMU/mL).</description>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to subjects receiving 100% dosage.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="426"/>
                <count group_id="O2" value="429"/>
                <count group_id="O3" value="340"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV 18 ≥ 24 mMU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="426"/>
                    <measurement group_id="O2" value="428"/>
                    <measurement group_id="O3" value="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 18 &lt; 24 mMU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (girls - women) must be greater than -5%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions
Miettinen and Nurminen, Stat Med 1985;4:213-26</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (boys - women) must be greater than -5%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions
Miettinen and Nurminen, Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) for HPV 18 by Week 4 Postdose 3</title>
        <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
        <population>subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to subjects receiving 100% dosage.</population>
        <group_list>
          <group group_id="O1">
            <title>Girls 10-15 Years</title>
          </group>
          <group group_id="O2">
            <title>Boys 10-15 Years</title>
          </group>
          <group group_id="O3">
            <title>Women 16-23 Years</title>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) for HPV 18 by Week 4 Postdose 3</title>
          <population>subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to subjects receiving 100% dosage.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="426"/>
                <count group_id="O2" value="429"/>
                <count group_id="O3" value="340"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="953.6" lower_limit="857.3" upper_limit="1060.7"/>
                    <measurement group_id="O2" value="1232.9" lower_limit="1105.6" upper_limit="1375.0"/>
                    <measurement group_id="O3" value="470.5" lower_limit="418.5" upper_limit="528.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (girls/women) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region and comparison group.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (boys/women) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region and comparison group.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Seroconverted for HPV 18 by Week 4 Postdose 3</title>
        <description>Seroconversion is defined as going from seronegative to seropositive.
Seropositivity is defined as an anti-HPV 18 titer ≥ 24 milliMerck units per milliliter (mMU/mL).</description>
        <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to female subjects 10-15 years and 16-23 years.</population>
        <group_list>
          <group group_id="O1">
            <title>20% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 20% dose formulation of the quadrivalent human papillomavirus (qHPV) vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
          <group group_id="O2">
            <title>40% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 40% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
          <group group_id="O3">
            <title>60% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 60% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O4">
            <title>100% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 100% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Seroconverted for HPV 18 by Week 4 Postdose 3</title>
          <description>Seroconversion is defined as going from seronegative to seropositive.
Seropositivity is defined as an anti-HPV 18 titer ≥ 24 milliMerck units per milliliter (mMU/mL).</description>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to female subjects 10-15 years and 16-23 years.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="406"/>
                <count group_id="O3" value="379"/>
                <count group_id="O4" value="766"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV 18 ≥ 24 mMU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="381"/>
                    <measurement group_id="O2" value="403"/>
                    <measurement group_id="O3" value="375"/>
                    <measurement group_id="O4" value="763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 18 &lt; 24 mMU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (partial dose - full dose) must be greater than -5%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions
Miettinen and Nurminen, Stat Med 1985;4:213-26</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (partial dose - full dose) must be greater than -5%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions
Miettinen and Nurminen, Stat Med 1985;4:213-26</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (partial dose - full dose) must be greater than -5%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <method_desc>Miettinen and Nurminen method for difference in proportions
Miettinen and Nurminen, Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) for HPV 18 by Week 4 Postdose 3</title>
        <time_frame>Week 4 Postdose 3 (Month 7)</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to female subjects 10-15 years and 16-23 years.</population>
        <group_list>
          <group group_id="O1">
            <title>20% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 20% dose formulation of the quadrivalent human papillomavirus (qHPV) vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
          <group group_id="O2">
            <title>40% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 40% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
          <group group_id="O3">
            <title>60% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 60% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O4">
            <title>100% Formulation qHPV Vaccine</title>
            <description>Subjects in this group received a 100% dose formulation of the qHPV vaccine at Day 1, Month 2, and Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) for HPV 18 by Week 4 Postdose 3</title>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data. Restricted to female subjects 10-15 years and 16-23 years.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="406"/>
                <count group_id="O3" value="379"/>
                <count group_id="O4" value="766"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="544.0" lower_limit="480.9" upper_limit="615.3"/>
                    <measurement group_id="O2" value="640.4" lower_limit="570.5" upper_limit="718.9"/>
                    <measurement group_id="O3" value="647.5" lower_limit="571.6" upper_limit="733.5"/>
                    <measurement group_id="O4" value="696.9" lower_limit="641.7" upper_limit="756.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (partial dose/full dose) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region and comparison group.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (partial dose/full dose) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region and comparison group.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (partial dose/full dose) must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region and comparison group.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were collected from subjects with follow-up.</desc>
      <group_list>
        <group group_id="E1">
          <title>20% Formulation</title>
          <description>Subjects in this group received a 20% dose formulation of the quadrivalent human papillomavirus (qHPV) vaccine at Day 1, Month 2, and Month 6.</description>
        </group>
        <group group_id="E2">
          <title>40% Formulation</title>
          <description>Subjects in this group received a 40% dose formulation of the quadrivalent human papillomavirus (qHPV) vaccine at Day 1, Month 2, and Month 6.</description>
        </group>
        <group group_id="E3">
          <title>60% Formulation</title>
          <description>Subjects in this group received a 60% dose formulation of the quadrivalent human papillomavirus (qHPV) vaccine at Day 1, Month 2, and Month 6.</description>
        </group>
        <group group_id="E4">
          <title>100% Formulation</title>
          <description>Subjects in this group received a 100% dose formulation of the quadrivalent human papillomavirus (qHPV) vaccine at Day 1, Month 2, and Month 6.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="496"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="509"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Tachycardia foetal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Cephalo-pelvic disproportion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Failed trial of labour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Hyperemesis gravidarum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Premature rupture of membranes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="509"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia nervosa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="509"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="434" subjects_at_risk="496"/>
                <counts group_id="E2" subjects_affected="426" subjects_at_risk="509"/>
                <counts group_id="E3" subjects_affected="431" subjects_at_risk="500"/>
                <counts group_id="E4" subjects_affected="1276" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="40" subjects_affected="35" subjects_at_risk="496"/>
                <counts group_id="E2" events="36" subjects_affected="31" subjects_at_risk="509"/>
                <counts group_id="E3" events="35" subjects_affected="29" subjects_at_risk="500"/>
                <counts group_id="E4" events="67" subjects_affected="65" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="157" subjects_affected="114" subjects_at_risk="496"/>
                <counts group_id="E2" events="163" subjects_affected="116" subjects_at_risk="509"/>
                <counts group_id="E3" events="157" subjects_affected="113" subjects_at_risk="500"/>
                <counts group_id="E4" events="436" subjects_affected="324" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="863" subjects_affected="402" subjects_at_risk="496"/>
                <counts group_id="E2" events="881" subjects_affected="395" subjects_at_risk="509"/>
                <counts group_id="E3" events="879" subjects_affected="395" subjects_at_risk="500"/>
                <counts group_id="E4" events="2535" subjects_affected="1184" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="179" subjects_affected="119" subjects_at_risk="496"/>
                <counts group_id="E2" events="201" subjects_affected="130" subjects_at_risk="509"/>
                <counts group_id="E3" events="172" subjects_affected="121" subjects_at_risk="500"/>
                <counts group_id="E4" events="500" subjects_affected="359" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="89" subjects_affected="72" subjects_at_risk="496"/>
                <counts group_id="E2" events="93" subjects_affected="69" subjects_at_risk="509"/>
                <counts group_id="E3" events="59" subjects_affected="51" subjects_at_risk="500"/>
                <counts group_id="E4" events="238" subjects_affected="196" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="496"/>
                <counts group_id="E2" events="36" subjects_affected="30" subjects_at_risk="509"/>
                <counts group_id="E3" events="32" subjects_affected="30" subjects_at_risk="500"/>
                <counts group_id="E4" events="70" subjects_affected="70" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="28" subjects_affected="25" subjects_at_risk="496"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="509"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="500"/>
                <counts group_id="E4" events="43" subjects_affected="39" subjects_at_risk="1498"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="202" subjects_affected="127" subjects_at_risk="496"/>
                <counts group_id="E2" events="176" subjects_affected="120" subjects_at_risk="509"/>
                <counts group_id="E3" events="221" subjects_affected="143" subjects_at_risk="500"/>
                <counts group_id="E4" events="490" subjects_affected="348" subjects_at_risk="1498"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Of note, the number of subjects who completed the Vaccination Period (N=1441) is slightly higher than that specified in the publication by Block, et al (2006; N=1430). The data provided here is based on final data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

